Zurcher Kantonalbank Zurich Cantonalbank Boosts Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 74.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,601 shares of the company’s stock after buying an additional 3,667 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Mirum Pharmaceuticals were worth $254,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 98.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after acquiring an additional 488 shares during the period. Teacher Retirement System of Texas purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $221,000. Arizona State Retirement System acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth approximately $222,000. E Fund Management Co. Ltd. purchased a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $223,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at approximately $251,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $26.39 on Tuesday. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $35.56. The business has a fifty day moving average of $26.06 and a 200-day moving average of $28.17. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -6.65 and a beta of 1.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million during the quarter, compared to analyst estimates of $66.73 million. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on MIRM shares. HC Wainwright reiterated a “buy” rating and issued a $58.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. JMP Securities boosted their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th. Stifel Nicolaus began coverage on Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They issued a “buy” rating and a $48.00 price objective for the company. Finally, SVB Leerink reduced their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Monday, March 18th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $51.70.

Insider Activity

In related news, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Eric Bjerkholt acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The disclosure for this purchase can be found here. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.